Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Short-term Investments: 2022-2025

Historic Short-term Investments for InMed Pharmaceuticals (INM) over the last 4 years, with Jun 2025 value amounting to $43,384.

  • InMed Pharmaceuticals' Short-term Investments fell 0.80% to $42,859 in Q3 2025 from the same period last year, while for Sep 2025 it was $42,859, marking a year-over-year decrease of 0.80%. This contributed to the annual value of $43,384 for FY2025, which is 0.74% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Short-term Investments of $43,384 as of FY2025, which was up 0.74% from $43,064 recorded in FY2024.
  • InMed Pharmaceuticals' 5-year Short-term Investments high stood at $44,804 for FY2022, and its period low was $43,064 during FY2024.
  • In the last 3 years, InMed Pharmaceuticals' Short-term Investments had a median value of $43,384 in 2025 and averaged $43,623.
  • As far as peak fluctuations go, InMed Pharmaceuticals' Short-term Investments declined by 3.06% in 2024, and later increased by 0.74% in 2025.
  • Yearly analysis of 4 years shows InMed Pharmaceuticals' Short-term Investments stood at $44,804 in 2022, then declined by 0.85% to $44,422 in 2023, then declined by 3.06% to $43,064 in 2024, then rose by 0.74% to $43,384 in 2025.